Welcome to our dedicated page for FSTX news (Ticker: FSTX), a resource for investors and traders seeking the latest updates and insights on FSTX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect FSTX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of FSTX's position in the market.
F-star Therapeutics, Inc. (NASDAQ: FSTX) announced a new study published in Nature Communications detailing the effectiveness of its second-generation STING agonist, SB 11285, in enhancing tumor control when combined with radiation for Head and Neck Squamous Cell Carcinoma (HNSCC). The research indicates that STING expression in tumors is vital for optimal benefits, suggesting that SB 11285 could serve as a predictive biomarker. Chief Scientific Officer Neil Brewis noted that clinical trials are ongoing to explore SB 11285's potential in cancer therapy.
F-star Therapeutics (NASDAQ: FSTX) has announced preclinical data on FS222, a tetravalent bispecific antibody targeting CD137 and PD-L1, which will be presented at the AACR Annual Meeting 2021. The study indicates that FS222's tetravalent mechanism leads to efficient receptor clustering and T cell activation, potentially enhancing treatment outcomes for cancer patients. The antibody shows a favorable safety profile and early signs of efficacy, with a Phase 1 trial already underway. These findings offer hope for improved immunotherapy options.
F-star Therapeutics, Inc. (NASDAQ: FSTX) has announced that Ares Trading S.A., part of Merck KGaA, has exercised its option to develop an additional bispecific program under their ongoing collaboration. This marks the third preclinical program licensed by Merck KGaA since their partnership began in 2019. The agreement entails an undisclosed option payment to F-star, along with future success-based milestones and royalties on net sales from these programs. CEO Eliot Forster expressed satisfaction with the collaboration, highlighting F-star’s proprietary platform's capabilities in immuno-oncology.
F-star Therapeutics, Inc. (NASDAQ: FSTX) announced its 2020 financial results, highlighting a successful NASDAQ listing and progress in its clinical programs. The company reported cash and cash equivalents of $18.5M, up from $4.9M in 2019, driven by PIPE financing and collaborations. R&D expenses decreased to $14.1M from $31.4M, while G&A expenses rose to $19.5M. A net loss of $25.6M was reported, equating to ($9.69) per share, compared to a loss of $23.0M or ($14.89) per share in the prior year. Notably, multiple clinical trials are underway, including FS118, FS222, and FS120.
F-star Therapeutics (NASDAQ: FSTX) announced an investor conference call set for March 29, 2021, at 9:00 a.m. EDT. The management team will discuss 2020 financial results and provide a corporate update. Interested participants can join via a live webcast or call 1-833-471-0868 for US/Canada and 1-914-987-7751 for international attendees. A replay of the call will be available from March 30, 2021, for 90 days. F-star is focused on developing bispecific antibodies for innovative cancer therapies, aiming to improve patient outcomes.
F-star Therapeutics (NASDAQ: FSTX) announced participation in two virtual conferences: the H.C. Wainwright Global Life Science Conference on March 9, 2021, and the Oppenheimer & Co 31st Annual Healthcare Conference on March 17, 2021. CEO Eliot Forster will lead fireside chats at both events, detailing the company's business strategy and updates on its clinical programs, particularly FS120 and FS222, which target CD137. These next-generation immunotherapies aim to enhance cancer treatment.
F-star Therapeutics announces the granting of European Patent number 3472207 for its lead clinical asset, FS118, protecting its composition throughout Europe until June 2037. This patent, effective January 20, 2021, enables F-star to advance its pipeline of tetravalent bispecific antibodies designed to treat cancer by targeting PD-L1 and LAG-3 receptors. CEO Eliot Forster emphasized the importance of this patent for ensuring exclusivity and advancing commercialization efforts for FS118, which aims to provide options for patients with limited treatment alternatives.
F-star Therapeutics, a clinical-stage biopharmaceutical company, announces participation in three upcoming virtual events: the H.C. Wainwright BioConnect Conference, LifeSci Advisors 10th Annual Corporate Access Event, and B Riley Oncology Investor Conference. CEO Eliot Forster will lead discussions and presentations detailing the company’s progress and pipeline. Key dates include January 6-14 for 1x1 meetings and January 20 for the investor conference. F-star aims to innovate cancer therapies through its proprietary bispecific antibodies and enhance patient outcomes.
F-star Therapeutics, Inc. (NASDAQ: FSTX) has initiated a Phase 1 trial for FS222, a bispecific antibody targeting CD137 and PD-L1, with the first patient dosed. This multicenter study aims to assess safety, tolerability, and clinical activity in adult patients with advanced malignancies. Preclinical data highlights FS222's ability to activate immune responses, showing significant tumor regression compared to traditional therapies. The drug targets immune-suppressing pathways, presenting potential advantages for patients with low PD-L1 expression.
F-star Therapeutics, Inc. (NASDAQ: FSTX) announced the dosing of the first patient in its Phase 1 trial for FS120, a dual-agonist bispecific antibody targeting CD137 and OX40, which aims to improve outcomes for cancer patients. The trial will evaluate FS120's effectiveness as a monotherapy and in combination with PD-1 monoclonal antibodies, focusing on 'cold' tumors. Preclinical results indicated delayed tumor growth and enhanced T cell activation. The company aims to transform treatment for patients with limited options.
